{"resourceType": "Evidence", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"], "versionId": "7", "lastUpdated": "2025-12-11T11:07:53.202Z"}, "identifier": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}], "text": "FEvIR Object Identifier"}, "system": "https://fevir.net/FOI", "value": "267242", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-secondaryOutcomeMeasure-4--OG000", "assigner": {"display": "Computable Publishing LLC"}}], "name": "NCT03421379_secondaryOutcomeMeasure_4_OG000", "title": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "note": [{"text": "Outcome Measure Population Description: All randomized participants who received at least one dose of study drug and had evaluable PK data."}, {"text": "Outcome Measure Denominator Units: Participants"}], "variableRole": "population", "observed": {"identifier": {"type": {"text": "ClinicalTrials.gov Outcome Measurement Group Id"}, "value": "OG000"}, "display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"variableRole": "outcome", "observed": {"type": "EvidenceVariable", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-secondaryOutcome-4", "assigner": {"display": "Computable Publishing LLC"}}, "display": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration -  (NCT03421379)", "reference": "EvidenceVariable/267231"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000574", "display": "median"}]}, "quantity": {"value": 0.25, "unit": "hour (h)"}, "sampleSize": {"knownDataCount": 71}, "attributeEstimate": [{"type": {"text": "Full Range"}, "range": {"low": {"value": 0.17, "unit": "hour (h)"}, "high": {"value": 0.67, "unit": "hour (h)"}}}]}], "id": "267242", "url": "https://fevir.net/resources/Evidence/267242", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "citeAs": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267242. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267242. Computable resource at: https://fevir.net/resources/Evidence/267242#json.", "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}